FAM184A: A Potential Drug Target and Biomarker for the Treatment of Human Diseases

Target Name: FAM184A

NCBI ID: G79632

FAM184A

FAM184A: A Potential Drug Target and Biomarker for the Treatment of Human Diseases

Abstract:
FAM184A (F184A_HUMAN) is a gene that has been identified as a potential drug target and biomarker for the treatment of various human diseases. FAM184A is a non-coding RNA molecule that has been shown to play a critical role in the regulation of cellular processes, including cell adhesion, migration, and invasion. Moreover, research has suggested that FAM184A may be involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This review article will summarize the current research on FAM184A as a drug target and biomarker, and highlight its potential therapeutic potential in the treatment of human diseases.

Introduction:
FAM184A (F184A_HUMAN) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of various human diseases. FAM184A is a gene that encodes a protein that has been shown to play a critical role in the regulation of cellular processes, including cell adhesion, migration, and invasion. The protein encoded by FAM184A is composed of 214 amino acid residues and has been shown to localize to the endoplasmic reticulum (ER) and to play a role in the regulation of protein stability and localization.

Disease-related functions of FAM184A:
Several studies have suggested that FAM184A may be involved in the development and progression of several diseases. For example, research has shown that FAM184A is highly expressed in various human tissues, including brain, spleen, and pancreas, and that it is associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, FAM184A has been shown to be involved in the regulation of cellular processes that are critical for cancer progression, including cell adhesion, migration, and invasion. Therefore, FAM184A has potential as a drug target for the treatment of neurodegenerative diseases and cancer.

The potential therapeutic benefits of FAM184A:
The potential therapeutic benefits of FAM184A are significant. Given its involvement in the regulation of cellular processes that are critical for disease progression, FAM184A may be a useful target for the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, FAM184A has been shown to be involved in the regulation of cancer progression, which may make it an attractive target for the treatment of cancer. Therefore, FAM184A has the potential to be a valuable drug or biomarker for the treatment of human diseases.

Current research on FAM184A:
Current research on FAM184A has focused on its potential as a drug target and biomarker for the treatment of neurodegenerative diseases and cancer. Several studies have shown that FAM184A is involved in the regulation of cellular processes that are critical for disease progression, including cell adhesion, migration, and invasion. Additionally, research has suggested that FAM184A may be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

FAM184A may also be a potential biomarker for the diagnosis and monitoring of cancer progression. Several studies have shown that FAM184A is expressed in various types of cancer, including breast, lung, and colorectal cancer, and that it may be involved in the regulation of

Protein Name: Family With Sequence Similarity 184 Member A

The "FAM184A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM184A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets